Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
ConvaTec Group Plc is a medical products and technologies company specializing in therapies for managing chronic conditions. It focuses on advanced wound care, ostomy care, continence and critical care, and infusion care, providing innovative solutions like ostomy pouches, wound dressings, continence catheters, and infusion devices for diabetes management. The company develops patient-centric technologies through rigorous research and development, emphasizing antimicrobial products, advanced tissue technologies, single-use disposable negative pressure wound therapy, pouch solutions, catheter products, and precision drug delivery. ConvaTec Group Plc serves healthcare providers and patients worldwide across these segments, with business areas including Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. Founded in 1978 and headquartered in London, United Kingdom, it operates in over 100 countries, delivering medical solutions that support ongoing treatment for chronic diseases.
15.83% operating margin is respectable but not wide. ROIC at 9.91%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 6.6%, steady but not accelerating.
Net debt of $1.45B represents 5.1x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
$2.44B
▲ +6.6% YoY
Net Income (TTM)
$175M
▼ -8.4% YoY
Op. Margin
15.83%
▲ +1.3pp YoY
ROIC
9.91%
▲ +1.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$285M
▲ +3.6% YoY
Op. Cash Flow (TTM)
$420M
▲ +39.9% YoY
Net Debt
$1.45B
Cash & Equiv.
$68M
3Y CAGR: +16.9%
3Y CAGR: +41.1%
Continue Research